Founded in 2020, Overland Pharmaceuticals is establishing a ******* cross-border platform company focused on advanced modalities through strategic partnering and in-house R&D. Overland is seeded by Hillhouse Capital with access to global innovation and China biopharma ecosystem.
Overland is building an initial oncology portfolio of ************** ADC and allogeneic cell therapy programs for greater China and Asia through partnering with established biotechs.
Through formative R&D partnerships and in-house technology platforms, Overland will move forward the development and commercialization of the most promising advances in medicine.